Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients
GLP1RA use in KT recipients with PTDM was not associated with graft or patient survival, though longer follow-up is necessary. GLP1RA use was associated with an increased risk of diabetic retinopathy, and care should be taken when initiating these agents.
Authors
- Mara McAdams‐DeMarco (ORCID: https://orcid.org/0000-0003-3013-925X)
- Krista L. Lentine (ORCID: https://orcid.org/0000-0002-9423-4849)
- Garyn Metoyer (ORCID: https://orcid.org/0000-0001-9894-2386)
- Dorry Lidor Segev (ORCID: https://orcid.org/0000-0002-1924-4801)
- Sunjae Bae (ORCID: https://orcid.org/0000-0003-0098-8816)
- Yiting Li (ORCID: https://orcid.org/0000-0001-6279-5740)
- Babak John Orandi (ORCID: https://orcid.org/0000-0001-6026-7135)
- Gayathri Menon (ORCID: https://orcid.org/0000-0002-5354-4840)
- Harris Z. Whiteson (ORCID: https://orcid.org/0009-0002-1670-4849)
- Yusi Chen (ORCID: https://orcid.org/0000-0001-6968-4664)
- Chenxi Gao
Institutions
- University of Missouri–St. Louis (US)
- NYU Langone Health (US)
- Saint Louis University (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1111/ctr.70354
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88